Table 1.
Demographics of all patients, and those included in the pharmacokinetic analysis after removing data with missing dose history or sample timing information
| Variable | All patients (n = 128) | PK patients (n = 117) |
|---|---|---|
| No. of TDM samples | 580 | 338 |
| No. of samples/patients, median (range) | 5 (1–14) | 3 (1–11) |
| Speciality, BMT/Haem/Imm/othera | 94/7/19/8 | 87/6/17/7 |
| Age, years (range) | 5.9 (0.5–18.9) | 5.7 (0.5–18.5) |
| Weight, kg (range) | 17.92 (6.05–71) | 17.8 (6.05–74.8) |
| Sex, male/female | 47/81 | 43/74 |
| Dose, mg (range) | 200 (32–700) | 200 (32–630) |
| Dose, mg/kg (range) | 12.99 (2.58–48.95) | 13.11 (2.67–48.95) |
| Dose, mg/m2, (range) | 326 (84–921) | 326 (84–921) |
| Concentration, mg/L (range) | 0.96 (0.07–4.99) | 0.8 (0.07–4.99) |
| Sample time after dose, h(range) | 6.96 (0.02–24.78) | 6.52 (0.02–24.78) |
| Dose frequency, doses/day (range) | 3 (1–4) | 3 (1–4) |
| % samples when patient had diarrhoea | 18 | 20 |
| % samples when patient also taking PPI | 61 | 68 |
| % samples when patient also taking H2 receptor antagonist | 28 | 32 |
BMT bone marrow transplant, Haem haematology, Imm immumology, H2 histamine H2-receptor antagonist, PK pharmacokinetic, PPI proton pump inhibitor, TDM therapeutic drug monitoring
a‘Other’ includes patients undergoing solid organ transplantation, those from gastroenterology, and surgical patients